孕产妇流感疫苗接种和相关的胎儿损失风险:基于索赔的前性队列研究
Annette K Regan1, Sheena G Sullivan2, Onyebuchi A Arah3
1School of Nursing and Health Professions, University of San Francisco, San Francisco, CA, United States; Department of Epidemiology, Fielding School of Public Health, UCLA, Los Angeles, CA, United States.
Vaccine
|September 11, 2024
概括
在怀孕期间接种流感疫苗是安全的,并且与胎儿损失风险的增加无关. 这些发现支持在怀孕前或怀孕期间接种流感疫苗的安全性.
科学领域:
- 产科和妇科 产科和妇科
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 现有的研究证实了在怀孕期间接种流感疫苗的安全性.
- 有限的研究已经探讨了流产风险或先前免疫接种的影响.
研究的目的:
- 为了评估流感疫苗接种和胎儿损失之间的关联.
- 评估与疫苗接种时间相关的风险 (在怀孕之前与怀孕期间).
主要方法:
- 一项基于索赔的队列研究,使用非识别的行政数据对117,626例怀孕 (2009-2018) 进行了分析.
- 通过CPT代码识别的流感疫苗接种;通过ICD-10-CM代码定义的胎儿损失.
- 考克斯的比例危险模型被用来评估胎儿损失的风险.
主要成果:
- 31.4%的队列接受了流感疫苗接种.
- 在怀孕期间接种疫苗与流产风险降低了39% (aHR为0.61).
- 在怀孕前接种疫苗和胎儿损失之间几乎没有观察到任何关联.
结论:
- 流感疫苗接种与胎儿损失的风险增加无关.
- 这项研究支持在怀孕前或怀孕期间接种流感疫苗的安全性.
更多相关视频
08:50A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
Published on: June 24, 2020
3.7K
07:13Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
Published on: March 25, 2016
18.3K
相关概念视频
Vaccinations
44.2K
Overview
44.2K
Development of Immunocompetence
294
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
294
Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
